Avis Budget Group Inc. (CAR)
NASDAQ: CAR
· Real-Time Price · USD
154.56
-5.15 (-3.22%)
At close: Oct 03, 2025, 3:59 PM
155.50
0.61%
After-hours: Oct 03, 2025, 07:53 PM EDT
-3.22% (1D)
| Bid | 147.28 |
| Market Cap | 5.44B |
| Revenue (ttm) | 11.61B |
| Net Income (ttm) | -2.22B |
| EPS (ttm) | -62.67 |
| PE Ratio (ttm) | -2.47 |
| Forward PE | 13.71 |
| Analyst | Hold |
| Dividends | n/a |
| Ask | 162.24 |
| Volume | 699,361 |
| Avg. Volume (20D) | 987,893 |
| Open | 161.42 |
| Previous Close | 159.71 |
| Day's Range | 154.38 - 161.50 |
| 52-Week Range | 54.03 - 212.81 |
| Beta | 2.02 |
| Ex-Dividend Date | n/a |
Analyst Forecast
According to 0 analyst ratings, the average rating for CAR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsAvis Budget Group Inc. is scheduled to release its earnings on
Oct 30, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-5.54%
Avis Budget Group shares are trading lower after B...
Unlock content with
Pro Subscription
2 months ago
-15.41%
Avis Budget shares are trading lower following worse-than-expected Q2 EPS and sales.
1 week ago · proactiveinvestors.co.uk
Hemogenyx Pharmaceuticals shares rise (again) as it inks agreement to commercialise CAR-THemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) shares advanced around 11% after announcing the signing of a letter of intent with Cellin Technologies, to explore the commercialisation of its HG-C...
